Organogenesis beats Q1 revenue guidance with $110.0M; net loss narrows to $2.1M

Organogenesis Holdings Inc.

2024-Q1 EPS reported -$0.02 revenue$109,976,000

Net revenue $110.0M, up 2% YoY, exceeding high-end of FY2024 guidance.
Advanced Wound Care revenue $103.9M (+3%); Surgical & Sports Medicine $6.1M (-9%).
GAAP net loss $2.1M ($0.02 EPS); adjusted net loss $1.4M; Adjusted EBITDA $2.6M.
FY2024 guidance reaffirmed: revenue $445M-$470M; adjusted EBITDA $15.8M-$35M.
Cash $89.3M, debt $64.9M as of March 31, 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Organogenesis Holdings Inc. reported first quarter ended March 31, 2024 results: revenue $110.0 million, net income $2.1 million, EPS $(0.02) per share. Guidance reaffirmed.

Period: first quarter ended March 31, 2024
Revenue: $110.0 million
Net income: $2.1 million
EPS: $(0.02) per share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31st, 2024. First Quarter 2024 Financial Results Summary: • Net revenue of $110.0 million for the first quarter of 2024, an increase of $2.3 million compared to net revenue of $107.6 million for the first quarter of 2023. Net revenue for the first quarter of 2024

View on SEC.gov

Browse all earnings releases →

Organogenesis Holdings Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-056885

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.